Cargando…
P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP
Autores principales: | Gotlib, Jason, Reiter, Andreas, Radia, Deepti, Deininger, Michael, George, Tracy, Panse, Jens, Vannucchi, Alessandro, Platzbecker, Uwe, Alvarez-Twose, Ivan, Mital, Andrzej, Hermine, Olivier, Dybedal, Ingunn, Hexner, Elizabeth O., Span, Lambert, Mesa, Ruben, Bose, Prithviraj, Pettit, Kirsten, Oh, Stephen, Lin, Hui-Min, Dimitrijevic, Sasa, Muñoz-González, Javier, Deangelo, Daniel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431238/ http://dx.doi.org/10.1097/01.HS9.0000970992.31848.76 |
Ejemplares similares
-
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
por: Gotlib, Jason, et al.
Publicado: (2021) -
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022) -
P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES
por: George, T., et al.
Publicado: (2022) -
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
por: DeAngelo, Daniel J., et al.
Publicado: (2021) -
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)